Skip to content

Rigel Pharmaceuticals RIGL Investing Cash Flow

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$716M-60.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$141.31M+25.5%
Nuvation Bio logo
Nuvation BioNUVB
-$43.64M-181%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$79.62M+655%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$3.06M-255%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$15.08M

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's investing cash flow?
Rigel Pharmaceuticals (RIGL) reported investing cash flow of -$7.98M in Q1 2026.
How has Rigel Pharmaceuticals's investing cash flow changed year-over-year?
Rigel Pharmaceuticals's investing cash flow increased by 24.4% year-over-year, from -$10.55M to -$7.98M.
What is the long-term trend for Rigel Pharmaceuticals's investing cash flow?
Over 3 years (2021 to 2025), Rigel Pharmaceuticals's investing cash flow has grown at a 2.2% compound annual growth rate (CAGR), from -$86.52M to -$92.37M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.